Diabetes represents one of the leading causes of death and disability in the Western world. Charles River helps accelerate novel discoveries through innovative target identification and validation, complex in vitro and in vivo pharmacology models, and a strong chemistry and disease biology foundation, all of which assist in translating basic research to clinical reality.
- In Vitro Capabilities
- In Vivo Study Models
- Disease-Related Biomarkers
- Scientific Resources
- Integrated Drug Discovery
In vitro expertise in support of your diabetes drug discovery program is vital to the successful development of novel therapeutics.
- Target discovery & validation
- Assay development & screening
- CRISPR gene editing
- Custom cell line generation
- Discovery chemistry
- Ion channel selectivity profiling
- Cardiac risk assessment
Related Resources
Charles River offers early research and proof-of-principle pharmacology studies in relevant animal models to assist your efficacy evaluations.
A broad panel of relevant biomarkers provides additional information on overall metabolic status. Browse our biomarkers by therapeutic area, toxicological indication, and species.
- Insulin
- Glucagon
- Leptin
- Resistin
- Adiponectin
- Non-esterified fatty acids
- Triglycerides
- Cholesterol
- HbA1c
- Fructosamine
- Custom multiplexed panels
Charles River is committed to advancing diabetes research. Access our latest scientific references and resources to learn more about our scientific contributions to this and other research areas.
We incorporate our scientific excellence, therapeutic area depth, innovative approach to drug discovery, and collaborative spirit to translate early stage projects into quality clinical candidates. We boast an enviable record of delivering over 75 development candidates and
Related Resources